Drug Type Synthetic peptide |
Synonyms rhSP-D |
Target- |
Mechanism Cell membrane permeability enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Start Date01 Sep 2021 |
Sponsor / Collaborator |
Start Date17 Aug 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Community Acquired Pneumonia | Phase 2 | US | 17 Aug 2021 | |
COVID-19 | Phase 2 | US | 17 Aug 2021 | |
Respiratory Failure | Phase 2 | US | 17 Aug 2021 | |
Influenza, Human | Preclinical | US | 14 Dec 2023 | |
Respiratory Syncytial Virus Infections | Preclinical | US | 14 Dec 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
ATS2024 Manual | Phase 1 | 37 | (sqhfpbtfob) = vxxnfehwsd jutrtjsnsv (jpvyssolte ) View more | Positive | 22 May 2024 |